SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
IMDX reported Third Quarter 2026 results. The price and volatility reaction is pending.
IMDXearnings

Earnings reactions, page 2

Insight Molecular Diagnostics Inc. (IMDX) Q3 FY2026 earnings

November 17, 2026 · SharpeIQ Research Desk

Reported results

  • Q3 2026 GAAP revenues were $559,000, compared to $260,000 in Q3 2025.
  • Q3 2026 GAAP gross profit was $420,000, representing a 75.1% gross margin, compared to $139,000 and a 53.5% gross margin in Q3 2025.
  • Q3 2026 GAAP net loss was $3.6 million, or $0.10 per share, compared to $10.9 million, or $0.34 per share, in Q3 2025.
  • Q3 2026 Non-GAAP net loss was $6.8 million, or $0.19 per share, compared to $7.0 million, or $0.22 per share, in Q3 2025.
  • Q3 2026 non-GAAP Adjusted EBITDA Loss was $6.3 million, compared to $6.6 million in Q3 2025.
  • Q3 2026 non-GAAP operating expenses were $6.7 million, flat year over year compared to $6.7 million in Q3 2025.

Guidance

  • The company targets outgoing free cash flow of approximately $8 million in the fourth quarter of 2026.

Notes

Reconciliation line-items for September 2025 were reclassified to conform to current presentation, though total Adjusted EBITDA loss reported for September 2025 remained unchanged.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →